Sanofi-Aventis ups its fight for diabetes crown with licensing deal
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis could pay up to $335 million for CureDM's preclinical novel human peptide Pancreate, a potential treatment for types 1 and 2 diabetes.